Anti-VEGF treatment for common diseases such as age-related macular degeneration and diabetic macular edema was associated with a lower CO<sub>2</sub>eq compared with treatment of patients suffering from less prevalent conditions such as uveitis (10.8 kg vs. 15.6 kg). Here, VEGFA is linked to diabetic macular edema.